Hologic Inc. ($HOLX) Stock Forecast: Up 0.3% Today

What is Hologic Inc.?

Hologic Inc. (HOLX) is a prominent company in the medical technology field, specializing in women's health, with divisions in Molecular Diagnostics, Breast Health, and GYN Surgical solutions. Today, HOLX saw a significant bullish movement in the market.

Why is Hologic Inc. going up?

HOLX stock is up 0.3% on Jan 5, 2026 17:20

• HOLX shares closed near their 52-week high, boosted by robust growth in key divisions and a proposed take-private deal, demonstrating investor confidence in the company's future.
• While HOLX lagged behind competitors like Danaher Corp. and Abbott Laboratories, its strong price performance and valuation suggest a positive outlook for current investors.
• Emphasis on precision oncology and diagnostic accuracy in healthcare, as discussed in an industry publication, may have contributed to heightened investor interest in Hologic's innovative products.
• In summary, today's bullish movement in HOLX likely stems from strong company performance, growth prospects in the sector, and potential opportunities in precision healthcare technologies.

HOLX Price Chart

HOLX Technical Analysis

HOLX News

Hologic Trading Near 52-Week High: How Should You Play the Stock?

Hologic's shares closed near their 52-week high, outperforming its industry and sector, driven by strong growth in Molecular Diagnostics, Breast Health, and GYN Surgical divisions, alongside a proposed $18.3 billion take-private deal. Despite macroeconomic headwinds and tariffs, the company's innovation, clinical evidence, and regulatory approvals suggest a "hold" position for current investors due to its favorable price performance and appealing valuation. Prospective buyers are advised to wait for more clarity.

https://finviz.com/news/267052/hologic-trading-near-52-week-high-how-should-you-play-the-stock

Hologic Inc. stock underperforms Thursday when compared to competitors

Hologic Inc. (HOLX) stock underperformed on Thursday compared to its competitors, such as Danaher Corp. and Abbott Laboratories. Despite the S&P 500's daily gain, Hologic's shares closed down 0.53%, while its peers saw gains.

https://www.msn.com/en-us/money/topstocks/hologic-inc-stock-underperforms-thursday-when-compared-to-competitors/ar-AA1yyjGt?apiversion=v2&noservercache=1&domshim=1&renderwebcomponents=1&wcseo=1&batchservertelemetry=1&noservertelemetry=1

RBC Sees Durable Growth Profile at Becton Dickinson (BDX), Raises Target

RBC Capital has raised its price target for Becton, Dickinson and Company (BDX) to $210 from $202, maintaining a Sector Perform rating, based on a forecast of mid-single-digit growth and a durable core business. However, the company faces a recent lawsuit alleging anti-competitive behavior in the surgical hernia mesh market. Despite potential, the article suggests other AI stocks might offer greater upside and less risk.

https://finviz.com/news/266386/rbc-sees-durable-growth-profile-at-becton-dickinson-bdx-raises-target

Smart Oncology: 5 Stocks Chasing the $317B Prize

The precision oncology market is rapidly expanding, projected to reach $317.5 billion by 2035, driven by a shift towards biomarker-guided cancer treatments. This article highlights five companies – Oncolytics Biotech Inc., Exact Sciences Corp., Veracyte, Inc., Hologic, Inc., and Personalis, Inc. – that are poised to capitalize on this significant growth by focusing on diagnostic precision and therapeutic targeting.

https://www.theglobeandmail.com/investing/markets/stocks/EXAS-Q/pressreleases/36839376/smart-oncology-5-stocks-chasing-the-317b-prize/

Abbott Laboratories (ABT): Buy, Sell, or Hold Post Q3 Earnings?

Abbott Laboratories (ABT) shares have declined by 7.9% over the past six months, prompting investor reevaluation. The company benefits from economies of scale and robust free cash flow margins, averaging 16.8% over five years. However, its long-term revenue growth has been a mediocre 6.4% compounded annually over the same period.

https://finviz.com/news/265732/abbott-laboratories-abt-buy-sell-or-hold-post-q3-earnings

Trending Today

Uniswap ($UNI) Crypto Forecast: Down 8.1% Today

Dogecoin ($DOGE) Crypto Forecast: Down 6.4% Today

Algorand ($ALGO) Crypto Forecast: Down 5.3% Today

Silver ($XAG) Commodity Forecast: Down 5.1% Today

Vaulta (prev.EOS) ($A) Crypto Forecast: Down 5.1% Today

ZCash ($ZEC) Crypto Forecast: Down 6.2% Today

Aave ($AAVE) Crypto Forecast: Down 5.3% Today

Astera Labs Inc ($ALAB) Stock Forecast: Up 6.9% Today

Blink Charging Co. ($BLNK) Stock Forecast: Down 5.1% Today

Teladoc Health Inc. ($TDOC) Stock Forecast: Down 5.0% Today

Hologic Inc. Price History

18.08.2025 - HOLX Stock was up 5.5%

• HOLX witnessed a significant upward movement in the market.
• The company's global presence remains robust, with strong growth in surgical products and increased utilization of diagnostics balancing out short-term obstacles.
• The spike in HOLX's stock value may be linked to the rejuvenation of its Breast Health segment, fueled by advancements in AI, changes in leadership, and product enhancements.
• Despite potential challenges ahead, investors appear positive about HOLX's future growth, driving the bullish trend in its stock performance.

03.10.2025 - HOLX Stock was up 0.2%

• Hologic's positive movement today is linked to an $18.3B buyout deal with Blackstone and TPG, sparking optimism and confidence among investors.
• Initial market uncertainty due to a fairness investigation by a law firm has transitioned into positive market sentiment towards the deal.
• Anticipation for Hologic's upcoming Q4 earnings is boosting investor confidence, expecting favorable results and growth.
• Despite an increase in short interest, overall market sentiment favors Hologic's current trajectory.

28.04.2025 - HOLX Stock was up 13.7%

• Recently, Hologic experienced a significant uptrend in its stock price, triggered by an undisclosed bid from TPG and Blackstone. The proposal values the company at $70-$72 per share, representing a notable premium compared to its prior close.
• The market's reaction signaled strong approval of the potential acquisition bid, reflecting investor confidence in Hologic's worth and its growth potential within the women's health sector.
• Despite encountering challenges such as tariff implications and reduced demand, Hologic's leading position in women's health diagnostics has placed it in a favorable position for prospective strategic collaborations and acquisitions, leading to an increase in its stock value.

05.00.2026 - HOLX Stock was up 0.3%

• HOLX shares closed near their 52-week high, boosted by robust growth in key divisions and a proposed take-private deal, demonstrating investor confidence in the company's future.
• While HOLX lagged behind competitors like Danaher Corp. and Abbott Laboratories, its strong price performance and valuation suggest a positive outlook for current investors.
• Emphasis on precision oncology and diagnostic accuracy in healthcare, as discussed in an industry publication, may have contributed to heightened investor interest in Hologic's innovative products.
• In summary, today's bullish movement in HOLX likely stems from strong company performance, growth prospects in the sector, and potential opportunities in precision healthcare technologies.

17.08.2025 - HOLX Stock was up 4.7%

• HOLX showed bullish movement, potentially influenced by:
• Optimism surrounding the revival of the company's Breast Health division, backed by AI advancements, leadership changes, and product enhancements.
• Investor confidence in HOLX's growth potential following these positive changes.
• Recent short-term bearish movement, which could be viewed as a minor fluctuation in the midst of HOLX's overall bullish trajectory driven by advancements in its Breast Health segment.

08.03.2025 - HOLX Stock was down 4.2%

• The addition of new leadership at Hologic may have initially been seen as a positive move, indicating potential stability and growth for the company.
• However, the mention of ongoing global uncertainties could have spooked investors, leading to a bearish movement in the stock.
• Investors may be cautious due to the uncertain global economic outlook, causing them to reevaluate their positions in HOLX despite its strong diagnostics strength and international potential.

02.04.2025 - HOLX Stock was down 8.5%

• Despite Hologic (HOLX) delivering a strong earnings and revenue beat in the second quarter of fiscal 2025, the stock experienced a bearish movement.
• The lowering of the EPS view for the future might have dampened investor sentiment, leading to the negative market reaction.
• The market could be reacting to macroeconomic turbulence, which might be impacting the overall sentiment towards the stock.
• Investors might be concerned about the potential impact of the lowered EPS view and the uncertainties in the macroeconomic environment, leading to the bearish movement in HOLX.

16.09.2025 - HOLX Stock was up 5.1%

• HOLX saw notable upward movement in the market today.
• This positive trend is potentially linked to the company's expanded fibroid treatment range bolstering growth within its GYN Surgical division.
• Optimism among investors and the resulting market upswing may have been influenced by the strong performance of the GYN Surgical section on an international scale, particularly with the increased availability of fibroid treatments.
• Despite a minor decline of -1.25% in HOLX's stock price in the most recent trading session, overall market sentiment appears positive, driven by the promising growth opportunities in the company's primary medical segments.

13.09.2025 - HOLX Stock was down 2.9%

• HOLX stock decreased by -1.25%, closing at $67.76.
• The bearish movement may stem from profit-taking by investors following a recent uptrend in the stock.
• Investor caution could be linked to competition in the medical diagnostic industry or overall market volatility affecting HOLX.
• Some investors could be reassessing their HOLX positions based on recent financial reports or guidance from the company.

10.06.2025 - HOLX Stock was up 3.0%

• The bullish movement in HOLX stock today can be attributed to the company's strong momentum in its GYN Surgical arm, driven by the success of Fluent Pro, global expansion efforts, and strategic acquisitions.
• Despite concerns raised about HOLX's low valuation and challenges in certain segments like Breast Health sales and risks in China, investors seem to be focusing more on the positive growth drivers in the GYN Surgical division.
• The market seems to be optimistic about Hologic's ability to capitalize on its strengths in women's health and surgical solutions, overlooking some of the short-term challenges highlighted.

24.11.2025 - HOLX Stock was down 0.6%

• Today, Hologic, Inc. (HOLX) saw a significant decline in the stock market due to various factors:
• Ongoing investigations by Brodsky & Smith concerning potential breaches of fiduciary duties by the company's board.
• Positive advancements in Hologic's AI technology for mammography being overshadowed by the investigations.
• Investor concerns over governance and acquisition practices within the company.
• General market apprehension towards companies facing fiduciary duty investigations impacting Hologic's stock performance negatively.

27.04.2025 - HOLX Stock was up 6.5%

• The bullish movement in HOLX today could be attributed to the positive comparison with Quest Diagnostics in terms of investor appeal and market performance.
• Investors may be favoring HOLX over DGX due to its strong position in the growing women's health sector, leading to increased buying activity and driving the stock price higher.
• Highlighting HOLX as a better pick compared to DGX might have sparked investor interest and confidence in the company's future prospects, contributing to the bullish market movement.